HIMUKA AM PHARMA
Himuka AM Pharmais a pharmaceutical company.
HIMUKA AM PHARMA
Industry:
Health Care Medical Device MHealth
Founded:
2017-02-01
Address:
Tokyo, Tokyo, Japan
Country:
Japan
Website Url:
http://www.himuka-am.com
Total Employee:
1+
Status:
Active
Total Funding:
5.51 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Kyungdong Pharm
Kyungdong Pharm is a pharmaceutical company.
Phapros
Phapros is a pharmaceutical company.
Tibet AIM Pharm
Tibet AIM Pharm is a pharmaceutical company that provides miglitol tablets, gualoupi injections, and hongjin xiaojie tablets.
Current Advisors List
Current Employees Featured
Founder
Investors List
Japan Science and Technology Agency
Japan Science and Technology Agency investment in Corporate Round - Himuka AM Pharma
MBLVC
MBLVC investment in Seed Round - Himuka AM Pharma
Mitsubishi UFJ Capital
Mitsubishi UFJ Capital investment in Seed Round - Himuka AM Pharma
Axil Capital
Axil Capital investment in Seed Round - Himuka AM Pharma
Nippon Venture Capital
Nippon Venture Capital investment in Seed Round - Himuka AM Pharma
Keio Innovation Initiative
Keio Innovation Initiative investment in Seed Round - Himuka AM Pharma
Miyazaki Taiyo Capital
Miyazaki Taiyo Capital investment in Seed Round - Himuka AM Pharma
Miyagin Venture Capital
Miyagin Venture Capital investment in Seed Round - Himuka AM Pharma
QB Capital
QB Capital investment in Seed Round - Himuka AM Pharma
Official Site Inspections
http://www.himuka-am.com
- Host name: s431-5.kagoya.net
- IP address: 133.18.34.13
- Location: Japan
- Latitude: 35.69
- Longitude: 139.69
- Timezone: Asia/Tokyo
More informations about "Himuka AM Pharma"
Himuka AM
Himuka am australia announces initiation for phase 1 clinical trial of hm201 in australia. 2021.11.04 nov. 4, 2021. hm201の第Ⅰ相臨床試験計画承認を受けました。 ...See details»
会社概要 – ひむかAMファーマ株式会社 - Himuka AM
Himuka AM Pharma Corp. Date of establishment. Feb. 1, 2017. Address. 2-5-36 Takachiho-dori, Miyazaki City, Miyazaki Prefecture 880-0812 Japan. CEO. Hiroshi Shinjo. Business summary. Development of Adrenomedullin …See details»
Himuka AM Pharma - Crunchbase Company Profile & Funding
Himuka AM Pharma is a pharmaceutical company focusing on the development of Adrenomedullin derivatives. Himuka AM Pharma creates drug candidates based on the …See details»
HIMUKA AM PHARMA CORP. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for HIMUKA AM PHARMA CORP. of MIYAZAKI, MIYAZAKI. Get the latest business insights from Dun & …See details»
Himuka AM Pharma - Products, Competitors, Financials, …
Himuka AM Pharma is a clinical-stage biotech company focused on the development of novel therapies for unmet medical needs. The company's main product is HM201, a novel …See details»
Himuka AM Pharma - Funding, Financials, Valuation & Investors
Himuka AM Pharma is a pharmaceutical company focusing on the development of Adrenomedullin derivatives. New. Resources. Advanced Search. Start Free Trial . Talk With …See details»
Himuka AM Pharma Corp.｜J-Startup
We develop drug seeds with a strong focus on derivatives of a bioactive peptide adrenomedullin (AM) which was discovered at University of Miyazaki (formerly Miyazaki Medical College). Our …See details»
Himuka AM Pharma Corp., Miyazaki, Japan - Wanderlog
Himuka AM Pharma Corp. is a business establishment renowned for its corporate headquarters. The company's primary office location, known as the corporate office, serves as the central …See details»
Himuka AM Pharma Corp. - VentureRadar
Himuka AM Pharma develops drug candidates with a strong focus on derivatives of a bioactive peptide adrenomedullin (AM) which was discovered at University of Miyazaki (formerly …See details»
Himuka AM Pharma Corp. - Drug pipelines, Patents, Clinical trials
Explore Himuka AM Pharma Corp. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, Disease Domain:Immune System Diseases, Technology Platform:Synthetic …See details»
Himuka AM Pharma Corp. - BIO International Convention | BIO
The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services. ... Himuka AM Pharma Corp. …See details»
Himuka AM Pharma Corp. | Portfolio - Keio Innovation Initiative / KII
Improved AM has been confirmed to be effective in animal experiments, and is currently being prepared for administration to humans. It is also expected to be applied to diseases such as …See details»
Himuka AM Pharma - Contacts, Employees, Board Members
Organization. Himuka AM Pharma . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 1. Number of …See details»
Himuka AM Pharma Corp. (Himuka AM Pharma Corp.) - 药物管线_ …
了解Himuka AM Pharma Corp. (Himuka AM Pharma Corp.)公司的药物管线，治疗领域，技术平台，以及它的1项临床试，疾病领域:免疫系统疾病，技术平台:合成多肽，小分子化药，药 …See details»
オーストラリアでのHM201の第Ⅰ相臨床試験が ... - Himuka AM
Apr 7, 2023 Himuka AM Pharma Corp. is a multi-asset clinical-stage biopharmaceutical company focused on developing novel treatments in areas of unmet need including refractory …See details»
Himuka AM Pharma - PitchBook
Sep 18, 2015 Himuka AM Pharma General Information Description. Developer of a bioactive peptide intended for mucosal healing and clinical remission. The company specializes in …See details»
ひむかAMファーマ株式会社｜J-Startup
ひむかAMファーマ株式会社は，宮崎大学医学部（旧・宮崎医科大学）で発見され，基礎研究・臨床研究が進められている生理活性ペプチド；アドレノメデュリン（Adrenomedullin, AM） …See details»
ひむかAMファーマ株式会社｜スピーダ スタートアップ情報リ …
Jan 13, 2022 生理活性ペプチドであるアドレノメデュリンの実用化に取り組む。 上皮細胞のバリア機能の修復・維持に関わるアドレノメデュリンを用いた炎症性腸疾患向け医薬品 …See details»
オーストラリアでのHM201の第Ⅰ相臨床試験を開始しました。 –
Dec 17, 2021 当社のオーストラリア子会社 Himuka AM Australia Pty. Ltd. が、開発品「 HM201 」の最初のヒト投与試験（ First-in-Human 試験）をオーストラリアで開始しました。. 開発 …See details»
HIMUKA AM AUSTRALIA ANNOUNCES HREC APPROVAL FOR …
Himuka's planned Phase 1 clinical trial of HM201 is designed as a double-blind, placebo-controlled, ascending dose, multi-cohort study in healthy subjects. The clinical trial will be …See details»